Prévention des crises cardiaques, Accidents vasculaires cérébraux et de la maladie rénale à travers une gestion intégrée de l'hypertension artérielle et du diabète

Objectives

The protocol adopts the World Health Organization Package of Essential Noncommunicable Disease interventions risk-based framework to prevent heart attacks, strokes and kidney disease through integrated management of hypertension, diabetes and tobacco use.[1][2][3]It uses hypertension, diabetes and smoking as entry points for identifying and managing cardiovascular risk, with prevention and treatment tailored to estimated 10-year risk of fatal or non-fatal cardiovascular events.[1][4]

• Identify and recruit adults aged over 40 years and people with relevant risk factors, including known hypertension, diabetes, obesity, smoking exposure, or family histories of premature cardiovascular, diabetic or renal disease.[1]
• Assess cardiovascular risk using World Health Organization/International Society of Hypertension charts for eligible patients aged over 40 who do not require referral, considering age, sex, smoking status, systolic blood pressure, diabetes status and, where available, total cholesterol.[4]
• Promote smoking cessation, regular physical activity, healthier diets, lower intake of total, saturated and trans fats, salt reduction, and increased consumption of fruit, vegetables, whole grains and legumes.[4][5][6]
• Provide risk-stratified counselling and clinical treatment for hypertension, dyslipidaemia and type 2 diabetes, while supporting patient and family education, weight management, hypoglycaemia prevention, eye screening and foot care.[5][6][3]
• Detect severe, secondary or malignant hypertension, cardiovascular disease, renal disease and diabetes complications, and escalate patients needing specialist assessment.[2][7][8]

Implementation

Implementation follows a staged clinical pathway of recruitment, structured assessment, referral decisions, cardiovascular-risk estimation, counselling, treatment and repeat review.[1][2][4]Technical support is associated with the Abidjan Institute of Cardiology, while oversight is assigned to the Ministry of Health and the directorate responsible for the National Programme for the Prevention of Non-Communicable Diseases.[1]The supplied material does not specify wider workforce roles, procurement arrangements, programme budgets, formal reporting systems or accountability mechanisms.[9][3]

• Undertake a first-visit assessment covering cardiovascular, cerebrovascular, diabetic and renal symptoms; current medicines; smoking and alcohol use; occupation and physical activity; and family history.[10]Conduct physical examination and tests including waist measurement, blood pressure, oedema assessment, cardiac, pulmonary and abdominal examination, diabetic foot examination, urine ketones and proteins, total cholesterol, and fasting or random blood glucose.[10][2]
• Use rapid blood-glucose meters where laboratory services are unavailable, and repeat relevant clinical and laboratory assessments at subsequent visits to identify changes in health status and lifestyle.[2][10]
• Provide lifestyle counselling for lower-risk patients and those with a 10% to less than 20% cardiovascular risk, including at least 30 minutes of moderate-intensity physical activity daily.[4][5]Advise salt reduction by at least one third, preferably to below 5 grams daily, and at least 400 grams of varied fruit and vegetables daily alongside whole grains and legumes.[5][6]
• Initiate or consider antihypertensive treatment according to risk category and blood-pressure persistence, including treatment at at least 160/100 mmHg, or at least 130/80 mmHg in people with diabetes.[5][6]For higher-risk patients, consider low-dose treatment when blood pressure remains above 140/90 mmHg, or at least 130/80 mmHg in diabetes, with selection informed by age, intolerance, reproductive potential and clinical circumstances.[9][11]Check serum creatinine and potassium before prescribing an angiotensin-converting enzyme inhibitor.[11]
• Manage lipid and glucose risk through dietary measures and indicated medicines, including statins for specified high cholesterol or type 2 diabetes, and metformin for clinically appropriate type 2 diabetes, followed by a sulfonylurea where metformin is contraindicated or ineffective.[6][11]The clinical annex also includes antihypertensive, lipid-lowering, antiplatelet and glucose-lowering medicine classes with indicative daily doses.[3][7]
• Monitor patients through a three-month second visit and continue three-month reviews until treatment objectives are achieved, then review at intervals of six to nine months.[6]Monitor blood pressure, blood glucose and urine regularly; arrange diabetic eye examination at diagnosis and subsequently every two years or as advised by the treating clinician; and encourage daily foot self-examination.[3]
• Refer patients to a Centre Hospitalier Universitaire or other appropriate specialist university hospital service for severe or complicated hypertension, suspected secondary hypertension, cardiovascular or renal disease, target-organ damage, treatment-resistant hypertension, specified diabetes complications, persistent cardiovascular risk above 30%, or suspected malignant hypertension.[2][12][3]Assess possible secondary hypertension linked to renal or endocrine disease, aortic coarctation or medicines, and recognise malignant hypertension through abrupt blood-pressure elevation and relevant retinal, cardiac, pulmonary, neurological and systemic signs.[7][8]

Monitoring & Evaluation

Monitoring is principally clinical and visit-based: the protocol uses initial assessment, repeat assessment at the second visit, and continuing risk-stratified follow-up to identify changes in symptoms, examination findings, laboratory results and lifestyle behaviours.[10][2][4]The supplied material does not establish a programme-wide monitoring and evaluation framework, standard performance indicators, routine reporting system, surveillance mechanism, audit process or formal accountability structure.[1][10][3][7][8]

• Assess cardiovascular risk at enrolment for adults aged over 40 years and other people with relevant risk factors or known hypertension, diabetes, obesity, smoking exposure, or relevant family history.[1]Estimate 10-year cardiovascular risk for eligible patients without referral criteria using World Health Organization/International Society of Hypertension charts, drawing on age, sex, smoking status, systolic blood pressure, diabetes status and, where available, total cholesterol.[4]
• Record clinical and behavioural information at the first visit, including cardiovascular, cerebrovascular, diabetic and renal symptoms; medication use; tobacco and alcohol use; occupation; physical activity; and family history.[10]Conduct examination and tests including waist measurement, blood pressure, oedema, cardiac, pulmonary, abdominal and diabetic-foot assessment, urine ketones and proteins, total cholesterol, and fasting or random blood glucose.[10]
• Repeat the relevant physical examination, laboratory assessment, referral decision and cardiovascular-risk assessment at the second visit, using the review to identify clinical or lifestyle changes.[10][2][4]Where laboratory testing is unavailable, use a rapid blood-glucose meter as an alternative means of measuring blood glucose.[2]
• Review patients every three months until treatment objectives are met, then schedule reviews at intervals of six to nine months.[6]For the higher-risk management actions described, review the patient after three months and repeat the assessment and management approach at subsequent visits.[11][13][12]
• Monitor hypertension, diabetes and renal-risk management through regular blood-pressure checks, blood-glucose testing and urine examination.[3]Include diabetic eye examination at diagnosis and subsequently every two years, or according to the treating clinician’s advice, and encourage daily self-examination of the feet.[3]
• Escalate care through referral to a Centre Hospitalier Universitaire or other appropriate specialised university hospital service when patients have severe, complicated or treatment-resistant hypertension; suspected secondary hypertension; cardiovascular or renal disease; target-organ damage; specified diabetes complications; persistent cardiovascular risk above 30%; or suspected malignant hypertension.[2][12][3]
• Identify possible malignant hypertension using symptoms and signs including headache, blurred vision, nausea, vomiting, lethargy, chest pain, dyspnoea, altered mental state, oliguria, abrupt blood-pressure elevation, retinal abnormalities, heart failure or pulmonary oedema, and neurological deficits.[8]
• Use the Ministry of Health and the Directorate responsible for the National Programme for the Prevention of Non-Communicable Diseases for protocol oversight, with technical support from the Abidjan Institute of Cardiology.[1]The excerpts do not specify reporting lines, data flows, publication requirements, sanctions, public accountability processes, or responsibility for reviewing aggregate performance.[1][3][7][8]

Costing & Financing

No explicit programme costing, budget, financing source, resource-mobilisation plan, funding gap, allocation, procurement budget or economic assumption is provided in the supplied excerpts.[1][2][5][9][13][3]The material identifies clinical inputs such as laboratory testing, rapid blood-glucose meters where laboratories are unavailable, medicines, repeat consultations and specialised referral, but does not attach prices, quantities, funding responsibilities or affordability assumptions to these inputs.[2][3][7]

• Require clinical resources for physical examinations, urine testing, total-cholesterol measurement, blood-glucose testing and cardiovascular-risk assessment, but do not specify the cost or financing of these services.[10][2][4]
• Identify indicative antihypertensive, lipid-lowering, antiplatelet and glucose-lowering medicines and dosages, but do not specify medicine prices, procurement arrangements, reimbursement mechanisms, stock requirements or supply-chain financing.[5][6][11][12][3][7]
• Require follow-up consultations, diabetic eye examinations, foot-care monitoring and referral to specialised services where indicated, but do not specify provider payment, patient costs, transport support, referral funding or the financial implications of service expansion.[6][12][3]
• Leave unspecified any domestic or external funding source, budget ceiling, fiscal period, resource gap, cost-effectiveness analysis, exchange-rate assumption, or method for estimating implementation costs.[1][2][5][9][13][3][8]